Navigation Links
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
Date:9/5/2012

LOS ANGELES and ROCKVILLE, Md., Sept. 5, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has entered into a collaboration and commercialization agreement with MacroGenics, Inc. Under the terms of the agreement, ImaginAb will develop an anti-CD3 clinical imaging product, for which MacroGenics may receive future milestones and royalties.  In addition, ImaginAb will support the development of companion imaging agents for B7-H3, a novel immune regulator target for which MacroGenics is developing therapeutics.

"Collaborating with MacroGenics provides the opportunity to demonstrate the ways in which ImaginAb's antibody fragment-based imaging technology can be used at the clinical nexus between cancer and immunology," said Dr. Christian Behrenbruch, Chief Executive Officer of ImaginAb. "We are glad to partner on both the B7-H3 and CD3 imaging programs as they are high-potential targets for the treatment of cancer and autoimmune diseases. The  recent clinical successes around key immune-directed targets in cancer, including those involving members of the B7 family of proteins, make these areas of research especially exciting. Our collaboration will augment ImaginAb's existing CD8 development program with an anti-CD3 imaging program."

"Imaging immune function is the next frontier of diagnostic medicine and will have a major impact on how new therapeutics are developed for cancer and autoimmune diseases," commented Dr. Scott Koenig, CEO of MacroGenics. "Our collaboration with ImaginAb should benefit our internal development programs targeting CD3 and B7-H3."   

Under the terms of the agreement, ImaginAb will develop a clinical imaging strategy based on a MacroGenics' anti-CD3 antibody as a patient selection tool for ongoing clinical programs, and will engineer a high-performance CD3 binding fragment for routine clinical imaging.  In addition, ImaginAb will develop imaging strategies and reagents for MacroGenics' anti-B7-H3 therapeutic product candidate, MGA271, and related applications for its CD3-based, Re-Directed T Cell Killing DART™ (Dual-Affinity Re-Targeting) therapeutic programs in cancer.

About ImaginAb

ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging.  The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of personalized medicine by improving patient outcomes and reducing the cost of healthcare.

For more information, visit www.imaginab.com.

About MacroGenics

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector cell function.  The company has multiple research and development collaborations with major pharmaceutical companies including Boehringer Ingelheim, Les Laboratoires Servier and Pfizer, Inc. 

For more information, visit www.macrogenics.com


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
2. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
3. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
4. Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor
5. GNS Healthcare And CHDI Foundation Collaborate To Build Computer Model Of Huntingtons Disease
6. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
7. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
8. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
9. Sanofi US Launches Collaborate Activate Innovation Challenge
10. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
11. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):